8-K: Rapport Therapeutics Reports Positive RAP-219 Data

Rapport Therapeutics announced sustained seizure reduction results from the Phase 2a follow-up period of its RAP-219 trial.

Summary

• Reported 8-week follow-up results for RAP-219 in focal onset seizures (FOS) following an 8-week treatment period.
• Observed a 90% median reduction in clinical seizures in weeks 9-12 and a 59% reduction in weeks 13-16 compared to baseline.
• Reported an 80% median reduction in long episodes (LEs) in weeks 9-12 and a 68% reduction in weeks 13-16.
• Updated the estimated half-life of RAP-219 to approximately 22 days, up from the prior estimate of 14 days.
• Confirmed RAP-219 was generally well tolerated with no treatment-related serious adverse events during the follow-up period.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, as the sustained efficacy and favorable pharmacokinetic data significantly de-risk the upcoming Phase 3 program.

Positives

• Demonstrated sustained efficacy in reducing clinical seizures and long episodes beyond the active treatment period.
• Longer-than-expected half-life (22 days) supports potential for sustained therapeutic effect and once-daily dosing.
• Generally well-tolerated safety profile with only two mild treatment-related adverse events during the follow-up period.
• Strong clinical data supports the initiation of two pivotal Phase 3 trials (FOCUS 1 and FOCUS 2) in Q2 2026.

Negatives

• Three patients experienced serious adverse events during the follow-up period, though none were deemed related to the study drug.
• Seizure freedom rates declined from 24% during the treatment period to 12% in the 1-16 week cumulative analysis.
• The study was an open-label, proof-of-concept trial with a small sample size (N=30).

Risks

• Clinical development is subject to uncertainties, including potential failure to achieve primary endpoints in upcoming Phase 3 trials.
• Dependence on third parties for clinical trial execution and manufacturing.
• Need for substantial additional capital to complete development and commercialization activities.
• Regulatory approval processes by the FDA and foreign authorities are complex and uncertain.
• Competitive landscape in the epilepsy and neurology market could impact commercial potential.

Future Outlook

The company plans to initiate two pivotal Phase 3 trials for RAP-219 in focal onset seizures in Q2 2026, expects initial data from an open-label safety trial in 2H 2026, and anticipates topline results for a bipolar mania trial in 1H 2027.

Management Comments

• Clinical outcomes improved further during the first four weeks after dosing ended, highlighted by a 90% reduction in clinical seizures, and consistent with the observed PK.
• These data demonstrate RAP-219's treatment effect in focal onset seizures out to 16 weeks of therapeutic drug exposure and furthermore show a consistent dose-exposure-clinical outcome relationship that provides us confidence in the doses we're advancing in Phase 3 trials.
• We believe these follow-up period results underscore the sustained activity of RAP-219 beyond the 8-week treatment period.

Industry Context

StockSavvy.ai notes that Rapport Therapeutics is positioning its precision medicine platform to address the high unmet need in drug-resistant epilepsy, a market segment currently dominated by traditional anti-seizure medications that often suffer from poor tolerability and complex drug-drug interactions.

Comparison to Industry Standards

• The 78% clinical seizure reduction observed in the treatment period compares favorably to existing anti-seizure medications where 30-40% of patients remain drug-resistant.
• The 22-day half-life is significantly longer than many conventional anti-seizure medications, potentially reducing the risk of breakthrough seizures caused by missed doses.
• The company's precision approach targeting TARP8 is differentiated from broad-spectrum AMPA receptor modulators that often cause systemic side effects.

Stakeholder Impact

• Shareholders: Positive clinical data increases the probability of successful commercialization and long-term value creation.
• Patients: Potential for a new, more effective, and better-tolerated treatment option for drug-resistant epilepsy.
• Clinicians: Provides a potential new tool with a differentiated mechanism of action and ease-of-use profile.

Next Steps

• Initiate Phase 3 FOCUS 1 and FOCUS 2 trials in Q2 2026.
• Continue open-label long-term safety trial.
• Advance IND-enabling activities for the long-acting injectable formulation.
• Prepare for Phase 2 bipolar mania topline results in 1H 2027.

Key Dates

Recommendation

The positive Phase 2a follow-up data, combined with a strong cash position and clear path to Phase 3, makes this an attractive opportunity for investors focused on clinical-stage biotechnology with high-conviction lead assets.

Keywords

Rapport Therapeutics, RAP-219, Focal Onset Seizures, Epilepsy, Phase 2a, Biotechnology, Clinical Trials, Neurology